ANT · Nasdaq · IPO research
Anthropic: growth has a price
Independent investment assessment
WaitWhat the US$83 offer requires
Offer reference · 2026-11-18
US$83.00
Provisional central intrinsic value
US$55.64
12-month fundamental value
US$60.33
Wait at the US$83 offer reference. Our provisional central intrinsic value is US$55.64; US$60.33 is twelve-month fundamental value, not a prediction of the trading price. The offer requires materially stronger operating economics, while closing capitalization and the cash bridge remain unverified.
Valuation cutoff 2026-11-18 · underwriting reviewed 2026-11-19 · USD. The offer is not a live quotation or guaranteed execution price. Fundamental value is not a forecast of the next year’s market price.
Valuation uncertainty: the base rate/growth sensitivity spans US$42.45–US$84.64 at 9–13% required return and 2–4% terminal growth. This is not a confidence interval or a complete downside bound.
Downside: the adverse operating case does not support positive sustainable terminal cash flow; no numerical bear value is assigned.
Evidence gap: final closing shares and cash are unverified. Market-price scenario: unavailable.
What would change the decision?
Reconcile final closing claims/cash and test whether customer collections and retained compute efficiency support stronger per-share economics.
Final capital and cash reconciliation
Test: Economic claims and available liquidity
Needed evidence: Final priced prospectus and completed closing/share/cash disclosures
Recalculate per-share value; keep provisional while material gaps remain.
Productive compute and cash conversion
Test: Utilization, unit costs, retained pricing and collections
Needed evidence: Reported compute payments, collections and comparable operating evidence
Replace proxy hypotheses with evidence and rerun price/compute stresses.
Actual entry economics
Test: Price versus revised intrinsic range and funding exposure
Needed evidence: Dated executable price and applicable investor costs/FX when considering an investment
Reassess expected return; no mechanical buy threshold or trading action.
Consider only after material claims and funding risks reconcile and a revised, stress-tested valuation supports an attractive actual entry. No automatic buy price or trade is authorized.
The strongest countercase
Research capability, enterprise integration and trust can support demand, but rivals and cloud partners can capture efficiency gains. The base explicitly assumes 3% annual price erosion, rising utilization and lower capacity/inference unit costs. These are testable analyst hypotheses, not reported operating metrics. The strongest countercase is a durable platform that retains more of its efficiency benefits.
Reverse DCF: the burden of proof
Each test solves one variable against the US$83 offer at an 11% USD required return and 3% terminal growth. These are alternative conditional hurdles, not uniquely identified market expectations.
Activity scale, all years
1.55× base
Activity changes in every forecast year; capacity and inference spending change with it. Realized pricing, utilization and unit-cost paths stay fixed. Training cash does not scale automatically.
Year-ten revenue US$856.9B · tested bounds 0.5–3×
Mature cash operating margin
42.9%
Only the mature cash margin changes. Explicit revenue, operating costs, cash flows, opening claims and terminal capital turnover stay fixed. The resulting margin must be justified independently.
Year-ten revenue US$551.9B · tested bounds 2.0%–60.0%
Operating drivers and valuation effects
Activity, utilization and unit-cost indices below are analyst hypotheses. They are not measured tasks, tokens, customers, channel segments or physical capacity. The first-year activity index is 100. Revenue is first-year revenue × activity growth × realized-price index. Capacity cash scales with activity ÷ utilization × capacity-unit cost; inference scales with activity × inference-unit cost; training is budgeted separately.
| Forecast year | Activity index | Realized-price index | Utilization assumption | Capacity-unit cost index | Revenue | Capacity / inference / training cash | Compute / revenue |
|---|---|---|---|---|---|---|---|
| 2027 | 100 | 100 | 65.0% | 100 | US$110B | US$60B / US$10B / US$10B | 72.7% |
| 2028 | 155 | 97 | 68.0% | 94 | US$165.4B | US$83.6B / US$14B / US$10.8B | 65.5% |
| 2029 | 220 | 94.09 | 71.0% | 88.36 | US$227.7B | US$106.8B / US$17.8B / US$11.7B | 59.8% |
| 2030 | 290 | 91.267 | 74.0% | 83.058 | US$291.1B | US$126.9B / US$21.1B / US$12.6B | 55.2% |
| 2031 | 370 | 88.529 | 77.0% | 78.075 | US$360.3B | US$146.3B / US$24.3B / US$13.6B | 51.1% |
| 2032 | 440 | 85.873 | 79.0% | 73.39 | US$415.6B | US$159.4B / US$26B / US$14.7B | 48.1% |
| 2033 | 510 | 83.297 | 81.0% | 68.987 | US$467.3B | US$169.4B / US$27.1B / US$15.9B | 45.4% |
| 2034 | 570 | 80.798 | 83.0% | 64.848 | US$506.6B | US$173.7B / US$27.3B / US$17.1B | 43.0% |
| 2035 | 620 | 78.374 | 84.0% | 60.957 | US$534.5B | US$175.5B / US$26.7B / US$18.5B | 41.3% |
| 2036 | 660 | 76.023 | 85.0% | 57.299 | US$551.9B | US$173.5B / US$25.6B / US$20B | 39.7% |
Cost indices begin at 100. Other central assumptions: operating cash 20% of revenue; future-service award economics 3%; positive modeled pretax tax rate 25%; owned capex 7%; working capital 5% of positive incremental revenue. None is issuer guidance. Channel-level reported margins are unavailable.
| Change from base | Current intrinsic | Difference | Annual model funding |
|---|---|---|---|
| Activity −20% | US$45.74 | US$-9.90 | Within modeled buffer |
| Activity +20% | US$65.55 | US$9.90 | Within modeled buffer |
| Realized price −20% | US$30.97 | US$-24.67 | Within modeled buffer |
| Compute cash +10% | US$47.62 | US$-8.02 | Within modeled buffer |
| Future award cost 5% of revenue | US$52.03 | US$-3.61 | Within modeled buffer |
| Activity versus base | Compute cash versus linked operating model | Intrinsic value | Annual model funding |
|---|---|---|---|
| 0.8× | 0.8× | US$58.78 | Within modeled buffer |
| 0.8× | 1.0× | US$45.74 | Within modeled buffer |
| 0.8× | 1.2× | US$32.50 | Within modeled buffer |
| 1.0× | 0.8× | US$71.59 | Within modeled buffer |
| 1.0× | 1.0× | US$55.64 | Within modeled buffer |
| 1.0× | 1.2× | US$39.52 | Within modeled buffer |
| 1.2× | 0.8× | US$84.41 | Within modeled buffer |
| 1.2× | 1.0× | US$65.55 | Within modeled buffer |
| 1.2× | 1.2× | US$46.54 | Within modeled buffer |
Activity changes revenue and linked capacity/inference costs. The compute multiplier then changes capacity, inference and training cash. These are stress combinations, not probabilities or measured efficiency forecasts.
Cash funding and quarterly liquidity
Eight equal-duration forecast quarters from the research date; analyst timing allocation, not disclosed calendar-quarter or covenant compliance. No option cash or new financing. Economic equity-award charge is noncash in this budget.
Conditional opening cash excluding future option exercises: US$232.1B. Base minimum modeled quarterly cash: US$228B. This does not establish intra-quarter solvency.
| Period end | Opening cash | Collections | Compute cash | Other cash uses | Noncash award cost — excluded | Ending cash | Buffer shortfall |
|---|---|---|---|---|---|---|---|
| 2027-02-17 | US$232.1B | US$27.5B | US$20B | US$8.5B | US$0.8B | US$231.1B | US$0B |
| 2027-05-19 | US$231.1B | US$27.5B | US$20B | US$8.5B | US$0.8B | US$230.1B | US$0B |
| 2027-08-19 | US$230.1B | US$27.5B | US$20B | US$8.5B | US$0.8B | US$229B | US$0B |
| 2027-11-18 | US$229B | US$27.5B | US$20B | US$8.5B | US$0.8B | US$228B | US$0B |
| 2028-02-18 | US$228B | US$41.3B | US$27.1B | US$13B | US$1.2B | US$229.2B | US$0B |
| 2028-05-19 | US$229.2B | US$41.3B | US$27.1B | US$13B | US$1.2B | US$230.4B | US$0B |
| 2028-08-18 | US$230.4B | US$41.3B | US$27.1B | US$13B | US$1.2B | US$231.7B | US$0B |
| 2028-11-18 | US$231.7B | US$41.3B | US$27.1B | US$13B | US$1.2B | US$232.9B | US$0B |
Cash uses include operating cash, taxes, owned capex and growth working capital. Award economics remain in valuation but are not counted as cash payments here. The US$5B buffer is an analytical threshold, not a covenant certification.
| Stress | Minimum quarterly cash | First buffer breach | Maximum buffer shortfall | Annual funding test |
|---|---|---|---|---|
| Base timing | US$228B | No modeled breach | US$0B | No annual breach |
| Price pressure: realized prices −20% | US$200.3B | No modeled breach | US$0B | No annual breach |
| Lower utilization: 20% below base | US$202.9B | No modeled breach | US$0B | No annual breach |
| Deployment spend front-loaded | US$207.5B | No modeled breach | US$0B | No annual breach |
| Collection delay: 50% of each quarter revenue | US$208.5B | No modeled breach | US$0B | No annual breach |
| Cash bridge US$25B lower | US$203B | No modeled breach | US$0B | No annual breach |
| IPO and placement proceeds unavailable | US$123.4B | No modeled breach | US$0B | No annual breach |
| Combined severe funding stress | US$-128.3B | 2027-08-19 | US$133.3B | Fails in forecast years 2, 3, 4, 5, 6, 7, 8, 9, 10 |
Pricing stresses change collections and taxes; lower-utilization stress increases capacity spending without assuming more revenue; deployment stress front-loads compute payments; delayed collections carry receivables into later quarters. Combined stress includes all of these, unavailable offering proceeds and an illustrative US$25B adverse cash bridge. Severities are analyst tests, not predicted outcomes.
The severe case has an unfinanced buffer shortfall of US$133.3B. No investable stress valuation or assumed capital raise hides that failure.
| Disclosed category | Amount | Timing / basis | Overlap and interpretation |
|---|---|---|---|
| Scheduled long-term obligations | US$320B | At September30; table p180 | Includes operating leases4224,financeleases1950,purchases313819; do not add its components again. |
| Scheduled remaining2026 | US$5.2B | At September30; remaining calendar2026 | Subset of319993; not a full-year or November-to-November amount. |
| Scheduled2027 | US$29.2B | Calendar2027 | Subset of319993; does not include all excluded commitments. |
| Scheduled2028 | US$44.4B | Calendar2028 | Subset of319993. |
| Short-term minimums excluded from table | US$17.4B | September30 contracts | Not included in319993; timing differs. |
| Uncommenced leases excluded from table | US$451.2B | September30; long dated | Not immediately payable; do not add all to first-year cash use. |
| Post-September minimum obligations | US$105.7B | Subsequent events | Different contract set and timing; excludes additional short-term6600. |
| Post-September short-term minimums | US$6.6B | Subsequent events | Do not confuse with September17.4Bshortterm pool. |
| Approximate next12month payments | US$70.7B | October1,2026–September30,2027 | Cross-cutting timing estimate including4200conditional/terminable; not additive to above pools and not an exact November forecast-year floor. |
| Conditional / precommencement termination arrangements | US$186.2B | Aggregate arrangements described p179 | Overlap with other categories; not an extra liability. |
Source: amended prospectus, MD&A Contractual Obligations and Notes 7, 13 and 17. Subsets and cross-cutting timing estimates must not be added together. The October 2026–September 2027 US$70.7B disclosure is not an exact floor for a different November-to-November forecast period.
Capitalization, cash and terminal reconciliation
Conditional legal pro-forma A+N shares: 13,203.574 million. Conservative economic claims: 18,199.67 million. Neither is a verified closing share register. Class T/F control rights are separate from economic participation.
| Adjustment | Change · million shares | Running economic shares · millions | Evidence status |
|---|---|---|---|
| Pre-offer A + N, after specified conversions and net settlement | 11,933.97 | 11,933.97 | conditional |
| New issuer shares at final offer price | 956.351 | 12,890.321 | conditional |
| Concurrent placement shares at US$83 | 313.253 | 13,203.574 | conditional |
| Existing gross options | 1,774.343 | 14,977.917 | derived |
| Existing unvested RSUs | 1,026.66 | 16,004.577 | derived |
| Post-September RSUs | 47.041 | 16,051.618 | derived |
| Acquisition issuances and holdback | 3.001 | 16,054.619 | derived |
| Post-September matching issuance | 27.992 | 16,082.611 | derived |
| Maximum existing vested matching obligation | 553.441 | 16,636.052 | derived |
| Full existing-note conversion | 1,840.445 | 18,476.497 | conditional |
| Less conversion already in pre-offer count | -276.828 | 18,199.67 | derived |
Reported, estimated and conditional amounts have different evidence status. Running totals are a reconciliation, not a verified closing register or bank statement.
| Adjustment | Change · US$ millions | Running cash · US$ millions | Evidence status |
|---|---|---|---|
| September unrestricted cash and short-term investments | 131,845 | 131,845 | disclosed |
| Gross primary issuance | 79,377.162 | 211,222.162 | conditional |
| Estimated issuance fees | -793.772 | 210,428.391 | estimate |
| Concurrent private placement | 26,000 | 236,428.391 | conditional |
| Estimated initial RSU withholding | -4,281.055 | 232,147.336 | estimate |
| Future option exercises — valuation convention only | 5,163.337 | 237,310.673 | conditional |
| Post-September cash adjustment — unresolved | 0 | 237,310.673 | unavailable |
Reported, estimated and conditional amounts have different evidence status. Running totals are a reconciliation, not a verified closing register or bank statement.
Acquisition issuances include an additional 1.590190 million holdback shares omitted previously. Gross option shares and exercise proceeds are paired once for valuation; liquidity excludes those prospective proceeds. Initial public benefit shares held in a subsidiary are conservatively treated as future economic claims. Existing awards are represented in shares; future service awards receive one economic cost. No ungranted reserve is automatically treated as outstanding.
| Case | Year-ten revenue / FCFF | Growth capex released | Explicit working capital released | Mature cash margin | Terminal cash before growth | Incremental growth investment | Terminal FCFF |
|---|---|---|---|---|---|---|---|
| bear | US$264.7B / US$-12.5B | US$7.9B | US$0.2B | -1.6% | US$-4.5B | US$4B | US$-8.5B |
| base | US$551.9B / US$114.9B | US$11B | US$0.9B | 23.0% | US$130.6B | US$6.6B | US$124B |
| bull | US$1,254.4B / US$404.8B | US$12.5B | US$5.7B | 33.7% | US$435.7B | US$12.5B | US$423.2B |
Mature margin uses year-ten operating cost/tax ratios and 5% maintenance capex. Terminal revenue grows 3%; growth reinvestment is incremental revenue divided by sales-to-capital (2× bear, 2.5× base, 3× bull). A cash-flow step-up can be legitimate when growth investment falls. Negative terminal cash is not repaired to manufacture a positive value.
Evidence, verification standard and model download
Every material assumption below is classified. Disclosed facts are linked to source locations; derived figures expose their bridge; estimates require rationale and sensitivity; conditional financing remains conditional. Independent arithmetic and source reconciliation are distinct from human analyst approval.
| Input / assumption | Value | Evidence type | Basis / calculation | Source location |
|---|---|---|---|---|
| Offer price | 83 | disclosed | Offer reference, not executable market quote. | November 18 final pricing announcement · November18 pricing announcement |
| Historical legal Class A | 2,168.788 | disclosed | Million shares at September30, before pro-forma adjustments. | November 17 amended prospectus · p26 capitalization reconciliation |
| Historical legal Class N | 30.643 | disclosed | Million shares at September30. | November 17 amended prospectus · p26 capitalization reconciliation |
| Preferred conversion A | 4,408.097 | conditional | Conversion immediately before offering closes. | November 17 amended prospectus · p26 capitalization reconciliation |
| Preferred conversion N | 4,153.018 | conditional | Conversion immediately before offering closes. | November 17 amended prospectus · p26 capitalization reconciliation |
| Initial cap-limited note conversion | 276.828 | conditional | Already included in pre-offer shares; subtract before adding full conversion. | November 17 amended prospectus · p26 capitalization reconciliation |
| Net initial RSU settlement | 49.755 | conditional | 101.333940m gross awards less51.578975m withholding. | November 17 amended prospectus · p26 capitalization reconciliation |
| Initial public benefit shares | 846.841 | conditional | Included once as conservative future economic claims; subsidiary-held shares differ from accounting outstanding shares. | November 17 amended prospectus · p26 additional adjustments |
| Acquisition holdback | 1.59 | disclosed | Missing from prior economic denominator; now included conservatively. | November 17 amended prospectus · p26 additional adjustments; Note15 |
| September liquidity | 131,845 | disclosed | US$m unrestricted cash plus short-term investments; excludes restricted cash. | November 17 amended prospectus · Consolidated Balance Sheets F6 |
| Initial withholding | 51.579 | derived | 101.333940×50.90%=51.57897546m shares; issuer rounded amounts; multiply actual83offer, not preliminary74. | November 17 amended prospectus · p24 RSU Settlement,50.90% assumption |
| Issuance fee | 0.01 | estimate | 1% of primary gross is an analyst estimate pending final prospectus; not verified final fee. | November 17 amended prospectus · Use of Proceeds; preliminary terms |
| Private placement | 26,000 | conditional | US$m; conditional closing, not existing cash. | November 17 amended prospectus · Concurrent Private Placement |
| Post-September cash movement | Unavailable / see schedule | unavailable | A zero modeling adjustment is not evidence of zero cash movement. Illustrative downside bridge subtracts US$25B. | November 17 amended prospectus · Latest statements September30; no current bank statement |
| Activity / price / utilization hypotheses | Unavailable / see schedule | estimate | Indices and utilization assumptions are not disclosed measurements or company guidance. Range and reverse-DCF tests expose the burden of proof. | November 17 amended prospectus · Business; MD&A; Risk Factors |
| Future award cost | 0.03 | estimate | 3% of revenue cash-equivalent economic charge covers future service awards and matching; no new share count added for the same charge. Noncash in liquidity budget. | November 17 amended prospectus · Equity Plans; Donation Matching Plan |
| Maintenance capex | 0.05 | estimate | 5% of revenue in mature state, separate from incremental growth investment. Not an issuer estimate. | November 17 amended prospectus · MD&A Infrastructure; Peralta model assumption |
| Required return / terminal growth | Unavailable / see schedule | estimate | Common11%USDrequiredreturn and3%terminalgrowth isolate operations; separate9–13% and2–4% sensitivity. No traded beta inference. | November 17 amended prospectus · Peralta scenario design |
SEC filing-index check · Targeted November19 inspection lists November17 S-1/A, November18 S-1MEF, registration and Form3 filings; no424B4orcompleted closing disclosure. Source check occurred in this review; no claim of a completed November20 closing.
Model: anthropic-ipo-decision-v2. The complete published inputs, scenarios, formulas’ outputs and reconciliation schedules are available in the downloadable model packet. This is a read-only snapshot of this publication, not an editable scenario tool.
Packet SHA-256: 5f89c9e7e0a8ae5d77ed3dc3b515f6cfd5d3f3224629d0c416696c0d2e662b38
Methodology informed by the actual 2026 CFA refresher readings inspected on the Mac mini: Equity Valuation: Applications and Processes, pp. 4–9; Introduction to Financial Statement Modeling, pp. 4–7. The independent Peralta analysis is not CFA Institute approval. No claim is made to a completed review of the 2026 FCFF chapter.
- Operating indices are analyst hypotheses; no absolute useful-work unit, channel revenue split or measured utilization is claimed.
- Quarterly timing is modeled, not a disclosed contractual calendar; no intra-quarter solvency or covenant certification.
- No final priced prospectus or completed closing was located in the November19 SEC index check.
- Post-September cash and net issuance costs are unverified; US$25B cash uncertainty is an illustrative stress, not an estimated actual burn.
- Future equity financing is not assumed; funding shortfalls remain visible. Existing awards are economic shares; future service awards are charged once as economic cost, not cash in liquidity.
- Reverse DCF is a conditional hurdle at fixed 11% / 3%, not uniquely inferred market expectations.
What changed in this edition
Capital claims corrected
Before: 18.198080B economic shares
Now: 18.199670B including acquisition holdback
Corrects omission; legal outstanding and economic claims remain distinct.
Operating assumptions separated from discount inputs
Before: Bull intrinsic US$194.19 at 9% required return/3.5% growth, with operating assumptions also changing
Now: Common 11%/3% operating cases; base US$55.64, upside US$162.16; adverse case not valued
Isolates operating outcomes; new indexed hypotheses also change cash forecasts, so this is not solely a rate effect.
Fundamental value relabeled and recalculated
Before: US$52.20 intrinsic; US$56.51 twelve-month target
Now: US$55.64 intrinsic; US$60.33 twelve-month fundamental value
Not a prediction of next year’s trading price. Recommendation remains Wait.
Financing risk made visible
Before: Annual economic-cash budget; all published scenarios required usable
Now: Quarterly cash timing, noncash-award separation, unavailable proceeds and explicit severe funding gap
No automatic rescue financing or hidden funding failure.
Publication proofreading
Before: Initial v2 prose contained spacing artifacts in several words and citations
Now: Corrected wording and source-locator typography; financial figures unchanged
Improves readability without changing the investment assessment or any numerical assumption.
Prior packet 68595c525f65cf5944ffa942fc6b365518b3a1703fe154f6564155ea11ce54df. The full prior edition is preserved in the trusted publication receipt; it has not been silently discarded. These are manual review checkpoints, not live monitoring or alerts.
Wait at the US$83 offer reference. Provisional central intrinsic value is US$55.64; US$60.33 is twelve-month fundamental value, not a market-price forecast. Final claims and the cash bridge remain unverified.
Company and research basis
ANT · Nasdaq · USD
Anthropic, PBC is a Delaware public benefit corporation founded in 2021 and headquartered in San Francisco. The issuer announced an IPO price of US$83 on November 18, 2026, with Nasdaq trading expected November 19 under ANT and closing expected November 20, subject to conditions. US$83 is the offering reference used here; it is not a verified opening trade, current quotation or attainable execution price.
Evidence: November 18 final pricing announcement · November 18 pricing announcement
What this report covers
Valuation cutoff is November 18, 2026; underwriting reviewed November 19 using the latest amended prospectus, issuer pricing and a targeted SEC filing-index check. Financial statements end September 30 and interim figures are unaudited. Closing and final priced capitalization remain unverified. This edition adds indexed operating assumptions, separate rate sensitivities, reverse valuation and cash-timing stresses. It supplies no observed trading price, measured channel split or market-price forecast.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Prospectus cover; Financial Statements F-6–F-14; pricing announcement
Investment summary
A strong product does not settle the investment case
Wait at the US$83 offer reference. Our provisional central intrinsic value is US$55.64; US$60.33 is twelve-month fundamental value, not a prediction of the trading price. The offer requires materially stronger operating economics, while closing capitalization and the cash bridge remain unverified. Revenue growth can create value only if retained pricing and productive capacity cover compute, staff, distribution, compensation and reinvestment. The recommendation is evidence-gated rather than a claim that the stock must fall to our value estimate.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Business; MD&A; Peralta FCFF model, base case
The disagreement is cash conversion
At 11% discounting and 3% terminal growth, the offer requires approximately 1.55× the base activity path with linked capacity and inference spending, or a 42.9% mature cash operating margin at unchanged revenue. The latter compares with the base-derived 23.0%. These are conditional alternative hurdles, not jointly required assumptions or uniquely inferred market beliefs.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Business; Risk Factors; Management’s Discussion and Analysis
Pricing changed the starting valuation
The final announcement increased the public offering from the roadshow’s 825 million shares to 980 million and set the price at US$83, above the initial US$70–78 range. Of the final shares, 956, 351, 354 are newly issued and 23, 648, 646 are sold by existing holders. Secondary proceeds do not fund Anthropic. The US$26 billion concurrent private placement is part of the provisional financing bridge, subject to its closing terms.
Evidence: November 18 final pricing announcement · November 18 pricing announcement
Operating leverage must survive capacity expansion
The base first annual forecast is US$110B revenue, ending at approximately US$551.9B in year 10. Activity rises 6.6×from its first-year index while realized yield declines 3% annually. Assumed utilization rises 65% to 85%; capacity-unit cost falls 6% and inference-unit cost 10% annually. These estimates require large adoption and efficiency gains; the company has not disclosed equivalent physical operating units that independently validate them.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Consolidated Statements of Operations F-7; Peralta base forecast
Our own target, with a wide range
Central intrinsic value is US$55.64; twelve-month fundamental value is US$60.33. The upside operating case gives US$162.16 current intrinsic value at the same 11%/3% discount assumptions. The adverse case has no positive sustainable terminal cash flow and no assigned price. This is an asymmetric set of conditional outcomes, not a probability range or market forecast.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Peralta FCFF model; Capitalization; Description of Capital Stock
Wait before adding
Wait before adding at the offer reference. Reassess when final claims and cash reconcile or new operating evidence changes retained pricing, compute cost, utilization or collections. Consider investing only after funding and concentration risks are acceptable and a revised valuation supports an attractive actual entry. There is no automatic buy price, promised margin of safety or trading instruction.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Peralta investment assessment; Risk Factors
Evidence that can change the thesis
Reassess on the final priced and closing share/cash reconciliation, evidence of cash retained after compute and reinvestment, and operating disclosures that test activity, pricing, utilization and efficiency. These are manual evidence checkpoints; no live monitoring or alerts have been activated. A stronger product does not necessarily create a near-term stock-price catalyst.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Shares Eligible for Future Sale; MD&A; Peralta thesis tests
The strongest countercase
The adverse operating case does not earn a positive sustainable terminal cash flow under its stated pricing, capacity and reinvestment assumptions; we therefore withhold a numerical bear valuation. This is more informative than inserting a positive terminal margin to rescue the result. A combined severe funding stress also exposes a cash shortfall. Both could require a financing or restructuring analysis outside this positive-perpetuity model. The cautious view could still be wrong if durable enterprise integration and efficiency support much stronger retained cash margins.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Business; Risk Factors; Peralta scenario analysis
Business description
A frontier model developer
Anthropic develops advanced AI models and provides access through its platform and applications. Its public benefit purpose gives responsible development a formal place in corporate governance. The economic question for shareholders is whether model capability, reliability and enterprise integration can create a durable stream of customer cash exceeding the recurring cost of training, inference, talent and infrastructure. A public benefit structure does not itself establish commercial advantage.
Evidence: November 17 amended prospectus · Business; Note 1, Description of Business
Subscriptions and usage monetize intelligence
Customers access Claude through subscriptions, enterprise arrangements and developer usage. The model combines recurring access with consumption-sensitive activity, so revenue can grow through more customers, wider deployment and more intensive use. Revenue quality depends on retention, realized prices and collections. It should not be treated as pure software subscription revenue with negligible marginal costs: each increment of inference can consume expensive compute, and channel distribution can carry significant fees.
Evidence: November 17 amended prospectus · Business; MD&A, Revenue and Sales, Marketing, and Partnerships
Claude across applications and development
Claude is the core model family underpinning customer-facing applications and developer access. Coding and workflow use broaden the opportunity beyond a general chat interface. The investment case depends on customers moving from experimentation to repeat production use, where reliability, security, latency and task completion matter. No standalone product segment profit is supplied here; consolidated results cannot be attributed to an individual application without a disclosed reconciliation.
Evidence: November 17 amended prospectus · Business, Products and Platform; MD&A
Adoption, usage and realized yield
Revenue expansion can come from new enterprise customers, broader deployment within existing accounts and greater usage per workflow. These drivers interact: lower unit prices may stimulate volume while reducing revenue per unit of computation. We therefore assess revenue together with compute cash and collections. A headline annualized run rate is not a substitute for recognized revenue, and a contract or capacity commitment is not customer cash already earned.
Evidence: November 17 amended prospectus · MD&A, Key Factors Affecting Performance and Revenue
Compute is central to the economics
Nine-month 2026 compute and infrastructure expense was US$18.808 billion; personnel expense was US$4.863 billion and sales, marketing and partnerships expense was US$5.529 billion. These categories do not form a conventional cost-of-revenue statement, so a GAAP gross margin cannot be reconstructed simply by subtracting compute expense. Training intensity, inference efficiency, hardware availability and partner charges all affect the cost of delivering growth.
Evidence: November 17 amended prospectus · Consolidated Statements of Operations F-7; MD&A expense definitions
A US issuer with a global supply chain
Anthropic is headquartered in the United States, while its supply chain depends on internationally concentrated semiconductor manufacturing and data-center inputs. The filing highlights Taiwan-related supply exposure and cross-border restrictions. This report does not assign an unsupported revenue-by-country mix. Customers’ geographic location, the location of compute and the domicile of the issuer create different regulatory, currency and continuity risks.
Evidence: November 17 amended prospectus · Note 1; Risk Factors, Supply Chain and International Operations
Measure useful work against its full cash cost
The most useful operating tests are customer retention and collections, useful tasks completed per unit of compute, utilization of committed capacity and the cost of acquiring and supporting enterprise usage. Better models can improve demand but also require new training expenditure. Efficiency creates value only to the extent it is retained after price competition and additional usage. The report therefore models compute cash explicitly rather than assuming a standard software margin.
Evidence: November 17 amended prospectus · Business; MD&A; Peralta model design
Partners widen reach and retain bargaining power
Direct enterprise and developer access coexist with distribution through major cloud partners. That reach can reduce friction for customers already buying through a cloud platform, but partner economics can reduce Anthropic’s retained revenue and strategic freedom. Some partners are also investors, infrastructure suppliers or competitors. Their combined role should be evaluated through contract terms and net cash retained, rather than treating every distribution relationship as an unqualified moat.
Evidence: November 17 amended prospectus · Business; MD&A, Sales, Marketing, and Partnerships; Related Party Transactions
Trust and legal rights are operating requirements
AI development faces privacy, copyright, safety, export-control and sector-specific restrictions. Customer confidence requires reliable handling of data and credible controls over model behavior. Compliance can constrain available data, deployment and capacity while raising cost. The filing’s litigation and risk disclosures provide evidence of exposure; an issuer’s safety commitments are not proof that all technical or legal risks have been resolved.
Evidence: November 17 amended prospectus · Risk Factors; Legal Proceedings; Note 13
Industry and competitive positioning
An industry joining research and infrastructure
Frontier AI combines model research, large-scale computing, application distribution and enterprise integration. It sits between capital-intensive infrastructure and software services. That mix makes conventional software comparisons incomplete: leading capability can attract customers, yet retaining it may require repeated training investment and access to scarce chips and power. Industry growth should be assessed alongside capital requirements and the distribution of profits between model vendors and suppliers.
Evidence: November 17 amended prospectus · Business; Risk Factors; Management’s Discussion and Analysis
Rapid adoption does not remove the cycle
Enterprise use is expanding quickly, but budgets, deployment approvals and returns on customer projects can constrain adoption. Capacity lead times can amplify the cycle when commitments are made before demand is certain. A slower customer rollout can leave fixed commitments underutilized; shortages can limit growth even when demand is strong. No third-party total-addressable-market forecast is used as a valuation input in this report.
Evidence: November 17 amended prospectus · Business; Risk Factors; Management’s Discussion and Analysis
Competition comes from several directions
Anthropic competes with other frontier model developers, large technology companies with their own models and distribution, and open or lower-cost alternatives. Hyperscalers can combine infrastructure, cash generation and existing customer channels. Smaller vendors can compete on specialization or price. The relevant test is whether Claude provides enough incremental customer value to retain demand and pricing after rivals improve, not whether it leads one benchmark at one moment.
Evidence: November 17 amended prospectus · Business; Risk Factors; Management’s Discussion and Analysis
Revenue establishes relevance, not measured share
The scale and growth of disclosed revenue demonstrate commercial traction. They do not establish a precise share of a consistently defined AI market: reported revenue across competitors can differ in product scope, gross-versus-net presentation and recognition. This report does not supply a fabricated market-share percentage. Positioning must be tested through retention, expansion and cash economics as comparable public disclosures develop.
Evidence: November 17 amended prospectus · Business; Risk Factors; Management’s Discussion and Analysis
A plausible moat still needs economic evidence
Research capability, a recognizable product, enterprise trust and integration into customer workflows may support differentiation. Switching can become harder when customers build processes around a model, but model access and applications are also changing rapidly. We view these as possible sources of advantage, not proven perpetual pricing power. Durable evidence would be strong retention and useful-work efficiency alongside a sustained margin after training and distribution costs.
Evidence: November 17 amended prospectus · Business; Risk Factors; Management’s Discussion and Analysis
Efficiency gains can be competed away
Improved inference efficiency can lower the cost of serving a task. The benefit to shareholders depends on whether prices fall at the same speed and whether increased usage requires more total capacity. A technically cheaper token is not automatically a higher cash margin. The base case assumes significant improvement over time but still includes large compute outlays; the bear case represents weaker retention of efficiency gains.
Evidence: November 17 amended prospectus · Business; Risk Factors; Management’s Discussion and Analysis
Scale creates barriers and replacement risk
Training frontier models requires talent, computing access and financial resources. Those barriers protect current scale but do not exclude substitutes, including specialized models, open alternatives or customer-built systems. Customers may route different tasks to different vendors. A successful model can therefore face pressure from both well-funded frontier rivals and cheaper tools that are sufficient for a narrower task.
Evidence: November 17 amended prospectus · Business; Risk Factors; Management’s Discussion and Analysis
Strategic dependence runs both ways
Large compute and hardware partners supply essential capacity and can finance expansion, while also distributing or competing with AI models. This creates access advantages and concentration risk together. The disclosed commitments are much larger than a routine variable software expense. Enterprise buyers can negotiate on price and diversify vendors; the strongest evidence of bargaining power is cash retained after both sides have been paid.
Evidence: November 17 amended prospectus · Business; Risk Factors; Management’s Discussion and Analysis
Physical and legal constraints can cap growth
Power connections, cooling water, permits and semiconductor availability can delay capacity. Copyright, privacy and AI-safety rules can alter development and deployment economics. These constraints need not move with customer demand and may affect competitors differently. Our required return and cash-cost scenarios reflect uncertainty, but they are not a quantified probability of a particular regulatory or infrastructure event.
Evidence: November 17 amended prospectus · Risk Factors, Infrastructure, Energy, Regulation and Litigation
Financial analysis
Revenue growth has outpaced operating expense
Revenue increased from US$2.545 billion to US$33.242 billion in the comparable nine-month periods, while operating expense rose from US$7.769 billion to US$34.502 billion. Operating loss narrowed to US$1.260 billion. The operating loss is distinct from the much larger US$104.039 billion net loss, which includes substantial financing remeasurement. Growth has improved the operating cost ratio, but profitability is not yet established across a full capacity cycle.
Evidence: November 17 amended prospectus · Statements of Operations F-7; MD&A
Financing explains most of the liquidity increase
September unrestricted cash and investments total US$131.845B. The pro-forma bridge adds conditional issuer proceeds and a US$26B private placement, deducts estimated fees and withholding, and shows option proceeds separately. The pre-IPO balance-sheet deficit includes financing measurement effects and redeemable preferred claims. It cannot be turned into a normal debt ratio or subtracted again after those claims are represented as converted shares.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Balance Sheets F-6–F-7; Cash Flows F-13
Positive operating cash needs a fuller bridge
Nine-month operating cash was US$6.569 billion. Deducting US$925 million of owned equipment purchases, US$1.955 billion of leased-asset and equipment prepayments and US$88 million of finance-lease principal leaves US$3.601 billion. This historical diagnostic is not normalized free cash flow: it includes working-capital timing and noncash compensation addbacks and does not capture every future contractual cash requirement.
Evidence: November 17 amended prospectus · Cash Flows F-12–F-14; Peralta arithmetic
The business has changed scale quickly
Revenue rose from US$41 million in 2023 to US$386 million in 2024 and US$4.585 billion in 2025, followed by US$33.242 billion in the first nine months of 2026. Comparisons begin from a very small base and span changing infrastructure and product scale. A mechanically extrapolated growth rate would overwhelm any realistic capacity or competitive analysis. We therefore model explicit annual revenue and costs rather than extending the historical percentage growth rate.
Evidence: November 17 amended prospectus · Statements of Operations F-7
Separate operating performance from financing marks
The nine-month US$94.324 billion fair-value financing charge is largely noncash and should not be projected as recurring compute cost. Removing it does not make all remaining earnings cash: US$3.255 billion of stock-based compensation, donation-matching liabilities and other financial-instrument adjustments also affect the reconciliation. We account for existing awards in diluted shares and prospective service awards in future economics, avoiding both omission and double counting.
Evidence: November 17 amended prospectus · Statements of Operations; Cash Flows; Notes on Financing and Stock Compensation
Cash is large; commitments are larger
Eight modeled quarters separate collections from compute and other cash uses. Future-service equity awards remain an economic charge in valuation but are noncash in this liquidity schedule. Equal-duration quarter timing is an analyst allocation from the research date, not an issuer payment calendar. The combined severe case overlays weaker prices, higher compute cash, front-loaded deployment, delayed collections, unavailable offering proceeds and a lower cash bridge; it exposes an unfinanced shortfall rather than assuming rescue capital.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Contractual Obligations; Liquidity; Peralta model liquidity review
Use transparent measures while earnings are negative
Nine-month operating margin is -3.8%, compared with -205.3% a year earlier; operating cash is 19.8% of revenue. Compute and infrastructure expense represents 56.6% of revenue, but this is an expense ratio, not a GAAP gross margin. Negative earnings make a P/E comparison uninformative. The separate ratios table shows the offer-based economic valuation and clearly labels annualized interim revenue as a simple scale reference.
Evidence: November 17 amended prospectus · Statements of Operations and Cash Flows; Peralta arithmetic
A demanding base case, not guidance
The central operating hypotheses produce year 10 revenue of US$551.9B and compute cash of US$219.1B, or 39.7% of revenue. Capacity, variable inference and training costs are derived separately. Mature cash margin of 23.0% uses 5% maintenance capex; incremental terminal growth is funded separately. These are Peralta assumptions requiring evidence, not guidance.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Peralta forecast; Contractual Obligations
Do not normalize away continuing economic burdens
The US$1.5 billion Bartz settlement charge in 2025 is separately identified rather than repeated mechanically. Financing marks also require separate treatment. In contrast, research expense, continuing employee incentives and the recurring cost of compute are central economic demands, even when their accounting presentation changes. We do not turn one favorable period of operating cash into an assumed permanent cash margin.
Evidence: November 17 amended prospectus · MD&A, Bartz Settlement; Cash Flows; Risk Factors
Valuation analysis
Ten explicit annual forecasts
The base activity index rises from 100 to 660, while annual price erosion of 3% reduces realized yield to approximately 76% of first-year yield. The resulting revenue path is derived from both assumptions. Activity is a normalized analytical index, not a disclosed task/token/customer count. Revenue-by-channel and physical throughput cannot be independently reconstructed from the current disclosure set; we do not manufacture those segments.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Peralta FCFF model, revenue schedules
Cash margin must include the full service burden
Compute cash is the sum of capacity commitments scaled by activity/utilization and unit cost, variable inference scaled by activity and unit cost, and a separate training budget. Other operating cash is 20% of base revenue; future-service award economics are 3%; cash tax is 25% of positive modeled pretax economics. The base-derived mature margin is 23.0%, while adverse operating economics do not support a positive perpetuity. No independent observed utilization or task-cost dataset is claimed.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Peralta FCFF model; Statements of Operations; Stock Compensation
Growth requires funded capital
Explicit base owned capex is 7% of revenue, with 5% of incremental revenue required for working capital. The mature state assumes 5% maintenance capex, followed by incremental growth investment using 2.5×sales-to-incremental-capital. The terminal bridge shows the release of explicit growth spending and working capital. Lease and hosting cash remain in compute and are not deducted again as the same financial debt.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Peralta FCFF model; Liquidity; Commitments
A USD required return, not a measured IPO beta
All operating cases use 11% USDrequired return and 3% terminal growth to isolate operating outcomes. A separate grid varies required return 9–13% andgrowth 2–4%. These are analyst assumptions, not an IPO beta or a measured market risk premium. Differences between the original combined bull outcome and the new common-rate operating case are explained in the revision history; the discount rate is not adjusted to make the offer appear reasonable.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Peralta FCFF model, discount assumptions
Most value still depends on the distant economics
Base year 10 economic free cash flow is US$114.9B. Terminal cash before incremental growth investment is US$130.6B; growth investment and the resulting terminal FCFF are shown in the model bridge. The mature margin is derived from year 10 costs with maintenance capex replacing total capex. The adverse terminal outcome remains nonpositive and is not repaired with an arbitrary positive margin.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Peralta FCFF model, terminal bridge
Use peers as economic checks
No matched-date public peer quotation set or Street target has been verified. The offer-based ratios remain transparent context; diversified technology firms are not interchangeable with a standalone frontier model developer. Reverse valuation is more useful here than importing an unsupported peer multiple: it shows what activity or mature cash economics would be needed to support US$83.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Business; Risk Factors; Peralta valuation methodology
Provisional value remains below the offer
Wait at the US$83 offer reference. Our provisional central intrinsic value is US$55.64; US$60.33 is twelve-month fundamental value, not a prediction of the trading price. The offer requires materially stronger operating economics, while closing capitalization and the cash bridge remain unverified. The updated denominator adds the acquisition holdback, and all operating cases now share discount assumptions. The resulting change is an underwriting revision, not evidence that the new point estimate is a precise market forecast.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Peralta FCFF model; Capitalization; pricing announcement
No numeric probability assigned
The report does not assign a calibrated probability of convergence to the target. A newly listed company has limited public evidence on execution, price discovery and shareholder behavior. Turning scenario labels into precise probabilities would suggest evidence we do not possess. The appropriate output is a conditional value range with explicit operating tests and uncertainty about both outcomes and timing.
Evidence: November 17 amended prospectus · Peralta scenario methodology
Evidence needed for greater confidence
Confidence should improve only when audited and interim public disclosures establish customer cash conversion, a reconciled post-closing share count, capacity deployment and the cost of sustaining model performance. The offer price is an issuer-announced transaction reference, not proof that the market agrees with a particular long-term forecast. We will reassess the model when operating evidence or final financing terms change, rather than treating elapsed time as convergence.
Evidence: November 17 amended prospectus · Peralta investment assessment; prospectus and pricing limitations
Scenario analysis
Bear: growth fails to absorb committed costs
Adoption grows, but pricing declines 5% annually, utilization reaches only 70%, and capacity-unit cost falls 6% annually. These are analyst stress assumptions, not disclosed operating metrics. The resulting mature cash economics are nonpositive after maintenance and growth investment. A positive-perpetuity DCF does not apply, so no intrinsic value or twelve-month fundamental value is assigned. This is not a zero-price prediction; financing, restructuring or a different recovery framework would need separate analysis.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Peralta FCFF model, bear case
Base: strong adoption, demanding cash burden
Activity rises 6.6× from first-year index while realized yield declines 3% annually; utilization improves from 65% to 85%. Capacity-unit cost declines 6%, variable inference-unit cost 10%, and training grows 8% annually. All are unverified analyst hypotheses requiring operating evidence. At the common 11% discount rate and 3% terminal growth, current intrinsic value is US$55.64 and twelve-month fundamental value is US$60.33. The five-year conditional annualized USD return from the offer reference is 0.4% after illustrative costs. No probability or forecast trading price is assigned.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Peralta FCFF model, base case
Bull: efficiency and enterprise adoption reinforce each other
Activity rises 11× and utilization reaches 90%, with stronger capacity and inference efficiency. First-year revenue is US$150B. Exceptional execution is required; no probability is assigned. At the common 11% discount rate and 3% terminal growth, current intrinsic value is US$162.16 and twelve-month fundamental value is US$178.56. The five-year conditional annualized USD return from the offer reference is 25.8% after illustrative costs. No probability or forecast trading price is assigned.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Peralta FCFF model, bull case
Market, Street and our central assessment
Operating outcomes now share 11% USDdiscounting and 3% terminal growth, with rates varied separately. There is no verified market-implied case, Street distribution or calibrated scenario probability. The base is a working central hypothesis, not a measured most-likely outcome. USD returns cannot be compared directly with MSCI ACWI IMI CAD without investor-specific FX and costs; XIC remains only the Canadian-sleeve comparator.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Peralta scenario and benchmark methodology
Investment risks
Capacity and model execution
Model training, inference reliability and capacity commissioning must work together. Chip delivery, data-center readiness and access to power and cooling can constrain service or leave assets underused. Technical leadership can decay quickly. Monitor productive capacity and customer outcomes rather than treating contracted capacity as delivered revenue; a missed deployment can weaken both the growth path and the cost position.
Evidence: November 17 amended prospectus · Risk Factors, Infrastructure, Model Development and Suppliers
Competition can transfer value to customers
Rival frontier models, hyperscaler bundling and lower-cost substitutes can reduce realized prices or retention. Suppliers may keep scarcity rents even when end-customer prices fall. A superior product today may require large recurring investment to remain competitive. Our cash-margin assumptions are therefore a material source of downside risk, particularly if efficiency gains benefit customers more than shareholders.
Evidence: November 17 amended prospectus · Risk Factors, Competition; Business
Annual cash tests can miss timing stress
The adverse operating case does not earn a positive sustainable terminal cash flow under its stated pricing, capacity and reinvestment assumptions; we therefore withhold a numerical bear valuation. This is more informative than inserting a positive terminal margin to rescue the result. A combined severe funding stress also exposes a cash shortfall. Both could require a financing or restructuring analysis outside this positive-perpetuity model. The quarterly cash schedule excludes option proceeds and does not certify intra-quarter solvency or legal covenant compliance. The US$25B cash-bridge stress is illustrative, not an estimate of actual cash burn.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Liquidity; Contractual Obligations; Capitalization
Copyright, privacy and safety exposure
Legal claims can affect access to training data, generate damages or require operational changes. Privacy, export-control and AI rules can limit deployment and raise compliance costs. The 2025 Bartz charge demonstrates that legal exposure can be financially material; it does not quantify all future claims. The report carries no assumption that safety policies eliminate model misuse, output errors or liability.
Evidence: November 17 amended prospectus · Risk Factors; Legal Proceedings; Note 13
Both our caution and our target can be wrong
The base requires strong adoption and sustained declines in compute cost per unit of activity. Efficiency may be passed to customers in lower prices, preventing those gains from reaching shareholders. Reverse valuation quantifies how much stronger activity or mature margin must be to justify the offer. Final share claims, unverified cash movements and operating proxies can still materially change the result; the point estimate should not conceal that uncertainty.
Evidence: November 17 amended prospectus · Peralta ANT decision model v 2; Peralta sensitivity review; Capitalization; Risk Factors
Environmental, social and governance
Power and water are material operating inputs
The filing identifies electricity availability, utility rate allocation, cooling-water scarcity and permitting as constraints on data-center economics. Higher temperatures and physical disruption can increase cooling requirements or interrupt service. Exposure exists through partners as well as owned infrastructure. We have not verified a complete comparable emissions, water-use or renewable-energy baseline for this report, so no ESG score, carbon-neutral claim or unsupported emissions estimate is assigned.
Evidence: November 17 amended prospectus · Risk Factors, Energy and Water; Environmental and Climate Disclosures
Trust depends on product behavior and data rights
AI output errors, misuse, security failures and privacy breaches can harm customers and weaken adoption. Training-data rights and copyright claims create obligations to creators as well as legal exposure. Skilled researchers and engineers are essential, with retention costs reflected in compensation and equity claims. The filing’s stated public-benefit and safety goals are relevant governance commitments, but they are not independent proof of safe outcomes or an absence of social harm.
Evidence: November 17 amended prospectus · Risk Factors, AI Safety, Privacy, Intellectual Property and Personnel; Legal Proceedings
Control differs from economic ownership
The Long-Term Benefit Trust’s Class T rights include authority over a board majority. Founder LLC’s Class F is designed to hold 50.1% of general voting power after the offering; these control shares do not carry ordinary economic participation. Class A and non-voting Class N provide different voting rights. The structure can protect a long-term mission while limiting outside shareholders’ ability to change direction or discipline management. It should be assessed as a tradeoff, not awarded an automatic governance premium.
Evidence: November 17 amended prospectus · Principal and Selling Stockholders, p.300–301; Description of Capital Stock; Governance
Material ESG risks transmit through cash and control
Power and water restrictions can delay capacity or raise compute costs. Data and safety failures can produce legal expense, customer loss and deployment limits. Mission-oriented control can permit decisions that favor the public benefit purpose over near-term shareholder returns. Strategic partners’ simultaneous roles as investors, suppliers and channels add conflict-management demands. No separate arbitrary ESG valuation haircut is layered on top of cash costs already modeled.
Evidence: November 17 amended prospectus · Risk Factors; Related Person Transactions; Peralta accounting of economic risk
Responsible execution can support enterprise adoption
Reliable systems, careful data handling and transparent oversight can help customers deploy AI in sensitive workflows. Better useful-work efficiency can also reduce resource use per task, although total energy and water demand may still rise with adoption. Evidence of these benefits should come from measurable outcomes, customer retention and resource disclosure. We treat them as opportunities requiring validation rather than assuming a sustainability advantage translates automatically into pricing power.
Evidence: November 17 amended prospectus · Business; Risk Factors; Peralta qualitative assessment
Valuation and profitability ratios
Offer-based reference, not a peer consensus
The following ratios use the US$83 offer reference, the fully converted economic share estimate and modeled opening cash from the same valuation packet. This differs from a basic legal-share market capitalization. Annualized nine-month revenue is a simple four-thirds scaling for context, not a forecast or trailing-twelve-month figure. No matched-date peer quotation set or Street consensus has been verified, so those numerical comparisons are unavailable.
Evidence: November 17 amended prospectus · Peralta arithmetic; Financial Statements; Capitalization
| Metric | Value / basis |
|---|---|
| Offer-based economic equity value | US$1,510.6B |
| Operating enterprise value proxy | US$1,273.3B |
| EV / FY2025 revenue | 277.7× |
| EV / annualized 9M2026 revenue | 28.7×; simple scaling only |
| 9M2026 operating margin | -3.8% |
| 9M2026 CFO / revenue | 19.8% |
| 9M2026 cash diagnostic / revenue | 10.8% |
| P/E / GAAP gross margin | Not meaningful / not separately presented |
| Numerical peer multiples / Street targets | Unavailable: no verified matched-date data |
Equity = offer price × economic diluted shares. EV proxy = equity less modeled opening cash; converted claims are included in shares and operating leases in compute cash. This is a model-based proxy, not a quoted provider EV. Swipe the table to view all columns.
Source: November 17 amended prospectus · Peralta capitalization and financial arithmetic
Income statements
Reported historical income statements
Selected consolidated US GAAP line items are shown in US$ millions. FY columns end December 31; the nine-month columns end September 30 and are unaudited. Interim periods are not full-year results. Financing fair-value charges are shown separately from operating expense. The full filing and accompanying notes remain the authoritative statements; no artificial quarterly or five-year listed history is supplied.
Evidence: November 17 amended prospectus · Consolidated Statements of Operations F-7
| US$ millions | FY2023 | FY2024 | FY2025 | 9M2025* | 9M2026* |
|---|---|---|---|---|---|
| Revenue | 41 | 386 | 4,585 | 2,545 | 33,242 |
| Compute and infrastructure | 433 | 2,522 | 7,326 | 4,381 | 18,808 |
| Personnel | 95 | 454 | 1,839 | 1,027 | 4,863 |
| Bartz settlement | 0 | 0 | 1,500 | 1,500 | 0 |
| Sales, marketing and partnerships | 2 | 43 | 568 | 322 | 5,529 |
| Other operating and administrative | 62 | 347 | 1,412 | 539 | 5,302 |
| Total operating expense | 592 | 3,366 | 12,645 | 7,769 | 34,502 |
| Operating loss | -551 | -2,980 | -8,060 | -5,224 | -1,260 |
| Interest income | 69 | 106 | 431 | 239 | 2,359 |
| Financing fair-value changes | -1,045 | -5,434 | -34,308 | -20,107 | -94,324 |
| Other income / expense | -2 | 0 | -8 | -3 | -10,397 |
| Total other expense | -978 | -5,328 | -33,885 | -19,871 | -102,362 |
| Pretax loss | -1,529 | -8,308 | -41,945 | -25,095 | -103,622 |
| Income tax expense | 2 | 1 | 20 | 12 | 417 |
| Net loss | -1,531 | -8,309 | -41,965 | -25,107 | -104,039 |
* Unaudited interim periods. Expenses are positive; losses are negative. No conventional cost-of-revenue or gross-profit line is manufactured. Swipe the table to view all columns.
Source: November 17 amended prospectus · Consolidated Statements of Operations F-7
Balance sheets
Pre-offering balance sheets
These are historical pre-offering balance sheets in US$ millions, not post-IPO capitalization. September 30, 2026 is unaudited. Convertible notes include fair-value measurement effects and redeemable preferred stock is presented outside stockholders’ equity. Applying their book carrying values as ordinary debt deductions on top of fully converted economic shares would mix incompatible valuation treatments.
Evidence: November 17 amended prospectus · Consolidated Balance Sheets F-6–F-7
| US$ millions | Dec2024 | Dec2025 | Sep2026* |
|---|---|---|---|
| Cash and equivalents | 3,141 | 17,388 | 95,562 |
| Short-term investments | 0 | 2,889 | 36,283 |
| Accounts receivable, net | 95 | 909 | 7,892 |
| Prepaid / other current assets | 2,076 | 2,560 | 1,283 |
| Total current assets | 5,312 | 23,746 | 141,020 |
| Restricted cash | 13 | 13 | 2,540 |
| Property and equipment, net | 19 | 146 | 3,061 |
| Operating lease ROU assets | 35 | 126 | 2,839 |
| Goodwill | 0 | 154 | 595 |
| Other noncurrent assets | 2,373 | 476 | 4,265 |
| Total assets | 7,752 | 24,661 | 154,320 |
| AP, accruals and other current liabilities | 333 | 2,511 | 9,426 |
| Operating lease liabilities, current | 13 | 37 | 274 |
| Deferred revenue | 28 | 269 | 1,971 |
| Total current liabilities | 374 | 2,817 | 11,671 |
| Operating lease liabilities, noncurrent | 39 | 80 | 2,536 |
| Convertible notes, carrying value | 14,116 | 41,677 | 130,502 |
| Other noncurrent liabilities | 150 | 823 | 1,974 |
| Total liabilities | 14,679 | 45,397 | 146,683 |
| Redeemable convertible preferred stock | 2,874 | 29,769 | 157,510 |
| Stockholders’ deficit | -9,801 | -50,505 | -149,873 |
* Unaudited. Restricted cash is separate from cash and equivalents. Totals include all statement categories; the identity assets = liabilities + redeemable preferred + stockholders’ deficit reconciles. Swipe the table to view all columns.
Source: November 17 amended prospectus · Consolidated Balance Sheets F-6–F-7
Cash-flow statements
Cash movements and the financing bridge
Selected US GAAP cash-flow lines are in US$ millions. Negative amounts are uses. Investment purchases are cash movements between liquidity categories and should not be mistaken for operating capex. Beginning and ending balances include restricted cash. The capital-spending diagnostic below adds leased-asset prepayments and finance-lease principal to owned equipment purchases, preserving the distinction between operating cash and cash retained after those uses.
Evidence: November 17 amended prospectus · Consolidated Statements of Cash Flows F-12–F-14
| US$ millions | FY2023 | FY2024 | FY2025 | 9M2025* | 9M2026* |
|---|---|---|---|---|---|
| Net loss | -1,531 | -8,309 | -41,965 | -25,107 | -104,039 |
| Stock-based compensation addback | 29 | 192 | 1,158 | 584 | 3,255 |
| Depreciation and amortization | 3 | 21 | 40 | 24 | 250 |
| Noncash financing fair-value adjustment | 1,045 | 5,434 | 34,308 | 20,107 | 94,324 |
| Donation matching liability | 0 | 0 | 541 | 0 | 2,086 |
| Other financial instruments | 0 | 0 | 0 | 0 | 10,277 |
| Other reconciliation | 0 | 7 | 11 | 4 | -11 |
| Receivables movement | -10 | -90 | -834 | -500 | -7,076 |
| Prepaids / other assets movement | -1,253 | -3,190 | 1,771 | 779 | 1,435 |
| AP / accruals / other liabilities movement | 84 | 222 | 2,079 | 1,867 | 4,377 |
| Lease liability movement | -1 | 0 | 13 | 24 | -11 |
| Deferred revenue movement | 7 | 21 | 241 | 194 | 1,702 |
| Operating cash flow | -1,627 | -5,692 | -2,637 | -2,024 | 6,569 |
| Owned equipment purchases | -2 | -15 | -131 | -111 | -925 |
| Leased-asset / equipment prepayments | 0 | 0 | -54 | -51 | -1,955 |
| Short-term investment purchases | 0 | 0 | -3,082 | -1,831 | -40,318 |
| Investment sales / maturities | 0 | 0 | 213 | 9 | 6,900 |
| Other investing | 0 | -7 | -23 | -23 | -248 |
| Investing cash flow | -2 | -22 | -3,077 | -2,007 | -36,546 |
| Preferred stock proceeds, net | 445 | 1,188 | 16,548 | 16,548 | 110,432 |
| Finance-lease principal | 0 | 0 | 0 | 0 | -88 |
| Convertible notes cash proceeds | 1,750 | 6,050 | 3,450 | 2,050 | 0 |
| Common stock cash proceeds | 3 | 10 | 111 | 59 | 407 |
| Common stock repurchases | 0 | 0 | -149 | -149 | 0 |
| SAFE proceeds | 122 | 0 | 0 | 0 | 0 |
| Offering costs paid | 0 | 0 | 0 | 0 | -16 |
| Financing cash flow | 2,320 | 7,248 | 19,960 | 18,508 | 110,735 |
| FX effect | 0 | 0 | 1 | 1 | -7 |
| Net cash increase | 691 | 1,534 | 14,247 | 14,478 | 80,751 |
| Beginning cash including restricted | 929 | 1,620 | 3,154 | 3,154 | 17,401 |
| Ending cash including restricted | 1,620 | 3,154 | 17,401 | 17,632 | 98,152 |
* Unaudited. All periods reconcile operating + investing + financing + FX to the change in cash, including restricted cash. Swipe the table to view all columns.
Source: November 17 amended prospectus · Cash Flows F-12–F-14
Independent valuation model
Ten annual nominal USD forecasts derive revenue from indexed activity and realized pricing. Capacity cash varies with activity, utilization and capacity-unit cost; inference and training are separate. These are analyst hypotheses, not measured tasks, tokens, channels or utilization. Other operating cash, future-service award economics, taxes, owned capex and working capital are charged explicitly. Mature cash margin reconciles year-ten costs to maintenance capex; terminal growth receives a separate capital charge.
bear
Conditional case · no probability assigned
- Current intrinsic
- Not valued
- 12-month fundamental value
- Not valued
- Return from offer
- Unavailable
- USD required return
- 11.0%
- Terminal growth
- 3.0%
- Terminal share of operating value
- Unavailable
- Five-year annualized return
- Unavailable
Adoption grows, but pricing declines 5% annually, utilization reaches only 70%, and capacity-unit cost falls 6% annually. These are analyst stress assumptions, not disclosed operating metrics.
No positive sustainable terminal cash flow. This model does not assign a price; it does not imply a zero trading price.
base
Conditional case · no probability assigned
- Current intrinsic
- US$55.64
- 12-month fundamental value
- US$60.33
- Return from offer
- -27.5%
- USD required return
- 11.0%
- Terminal growth
- 3.0%
- Terminal share of operating value
- 70.4%
- Five-year annualized return
- 0.4%
Activity rises 6.6× from first-year index while realized yield declines 3% annually; utilization improves from 65% to 85%. Capacity-unit cost declines 6%, variable inference-unit cost 10%, and training grows 8% annually. All are unverified analyst hypotheses requiring operating evidence.
bull
Conditional case · no probability assigned
- Current intrinsic
- US$162.16
- 12-month fundamental value
- US$178.56
- Return from offer
- 114.7%
- USD required return
- 11.0%
- Terminal growth
- 3.0%
- Terminal share of operating value
- 68.6%
- Five-year annualized return
- 25.8%
Activity rises 11× and utilization reaches 90%, with stronger capacity and inference efficiency. First-year revenue is US$150B. Exceptional execution is required; no probability is assigned.
A terminal contribution above 100% means explicit forecast losses offset part of the discounted terminal value. These wide cases reflect substantial uncertainty, not calibrated probabilities.
All operating cases share an 11% USD required return and 3% terminal growth. A separate grid varies discounting from 9% to 13% and growth from 2% to 4%. These are analyst assumptions, not a measured IPO beta or uniquely inferred market expectations.
Cash and dilution bridge
- Gross new primary proceeds
- US$79.4B
- Secondary proceeds to selling holders
- US$2B
- Modeled opening cash and investments
- US$237.3B
- Fully converted economic share estimate
- 18.20B
- Nine-month cash after owned capex, prepayments and finance-lease principal
- US$3.6B
The economic denominator includes gross existing options, unvested awards, matching obligations, acquisition issuances and holdback, initial benefit shares and full existing-note conversion less the conversion already included in pre-offer shares. Legal pro-forma shares and voting rights are distinct. Option proceeds are a valuation convention and are excluded from liquidity. Existing awards are represented in shares; prospective service awards are charged once as economic cost.
The US$70.7 billion contractual amount covers October 2026 through September 2027. It is not an exact minimum for a forecast year beginning November 18. The obligation register separates dated scheduled payments, excluded and subsequent contracts, and overlapping conditional subsets. Forecast compute cash includes hosting and lease service; the same payments are not deducted again as debt.
Base annual cash-flow forecast · USD billions
| Year | Revenue | Compute cash | Owned capex | Free cash flow | Economic retained cash |
|---|---|---|---|---|---|
| 2027 | 110.0 | 80.0 | 7.7 | -7.5 | 229.9 |
| 2028 | 165.4 | 108.3 | 11.6 | -0.1 | 229.8 |
| 2029 | 227.7 | 136.3 | 15.9 | 10.2 | 240.0 |
| 2030 | 291.1 | 160.7 | 20.4 | 24.1 | 264.1 |
| 2031 | 360.3 | 184.2 | 25.2 | 41.3 | 305.3 |
| 2032 | 415.6 | 200.1 | 29.1 | 58.1 | 363.4 |
| 2033 | 467.3 | 212.4 | 32.7 | 75.3 | 438.7 |
| 2034 | 506.6 | 218.1 | 35.5 | 91.6 | 530.3 |
| 2035 | 534.5 | 220.7 | 37.4 | 104.4 | 634.7 |
| 2036 | 551.9 | 219.1 | 38.6 | 114.9 | 749.6 |
Free cash flow also deducts staff, research and distribution cash, future-service award costs, taxes and incremental working capital. This retained-cash path includes the economic award charge. Actual cash funding is analyzed separately above, with noncash awards excluded. Zero future partner-facility proceeds, buybacks or dividends are assumed.
Five-year investment assessment
Base conditional annualized return: 0.4% through November 18, 2031.
Conditional USD five-year stock returns use the US$83 offer as an entry reference, zero dividends and illustrative 10 basis points each-way trading costs. The IPO price is not a guaranteed retail fill or opening trade. Canadian investor FX and account-specific fees are unverified. The portfolio comparator remains MSCI ACWI IMI CAD net total return over rolling five-year periods; no benchmark forecast or alpha probability is supplied.
Required-return and terminal-growth sensitivity
| Required return | Terminal growth | 12-month fundamental value |
|---|---|---|
| 9.0% | 2.0% | US$73.97 |
| 9.0% | 3.0% | US$81.10 |
| 9.0% | 4.0% | US$91.08 |
| 11.0% | 2.0% | US$56.85 |
| 11.0% | 3.0% | US$60.33 |
| 11.0% | 4.0% | US$64.80 |
| 13.0% | 2.0% | US$46.27 |
| 13.0% | 3.0% | US$48.17 |
| 13.0% | 4.0% | US$50.50 |
Assumptions and evidence limits
Final priced and closing capitalization remain unverified. September liquidity is not a November cash balance; zero intervening cash adjustment is an unresolved placeholder, tested with an illustrative US$25 billion adverse bridge. Fees and withholding remain estimates. Quarterly allocations are timing hypotheses, not disclosed calendar quarters or covenant compliance. The adverse operating case has no positive sustainable terminal cash and receives no numerical valuation. No current trading quote, calibrated probability, CAD FX return or benchmark forecast is provided.
Financial facts through 2026-09-30. Reviewed by an AI analyst; forecasts and valuation assumptions are Peralta estimates.
Primary sources
- November 17 amended prospectus
Capitalization pp. 130–136; notes pp. 173–179; financials F-5–F-13; awards and matching pp. 23–24. All share amounts are post-split.
- November 18 final pricing announcement
US$83; 980 million public shares, including 956.351354 million primary and 23.648646 million secondary; 147 million optional overallotment; expected November 19 trading and November 20 closing.